V

Vital Prospects Clinical Research Institute, PC | Tulsa, OK

Research site
(Unclaimed)
Location
7307 S Yale Avenue, Suite 200, Tulsa, Oklahoma, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

10 of 27
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and...

Enrolling
Primary Immunodeficiency Diseases (PID)
Biological: TAK-881
Biological: HYQVIA

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Baricitinib
Drug: Placebo

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There...

Active, not recruiting
Psoriasis
Drug: Ustekinumab
Drug: Risankizumab

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheez...

Enrolling
Wheezing Lower Respiratory Illness
Recurrent Wheezing
Drug: Placebo
Drug: OM-85
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib
Status recently updated

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Active, not recruiting
Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermat...

Active, not recruiting
Atopic Dermatitis
Eczema, Atopic
Drug: etrasimod
Drug: Placebo

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Oral EP262
Drug: Placebo

Trial conditions

Atopic Dermatitis (11 trials)
Dermatitis (11 trials)
Eczema (10 trials)
Psoriasis (5 trials)
Alopecia (3 trials)
Alopecia Areata (3 trials)
Immunologic Deficiency S... (3 trials)
Primary Immunodeficiency... (3 trials)
Asthma (2 trials)
Chronic Urticaria (2 trials)

And 14 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems